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Background: Disruption of gastrointestinal tract epithelial and immune barriers contrib-
ute to microbial translocation, systemic inflammation, and progression of HIV-1 infection. 
Antiretroviral therapy (ART) may lead to reconstitution of CD4+ T cells in gut-associated 
lymphoid tissue (GALT), but its impact on humoral immunity within GALT is unclear. 
Therefore, we studied CD4+ subsets, including T follicular helper cells (Tfh), as well as 
resident B cells that have switched to IgA production, in gut biopsies, from HIV+ subjects 
on suppressive ART compared to HIV-negative controls (HNC).
Methods: Twenty-three HIV+ subjects on ART and 22 HNC undergoing colonoscopy 
were recruited to the study. Single-cell suspensions were prepared from biopsies from 
left colon (LC), right colon (RC), and terminal ileum (TI). T and B lymphocyte subsets, as 
well as EpCAM+ epithelial cells, were accurately enumerated by flow cytometry, using 
counting beads.
results: No significant differences in the number of recovered epithelial cells were 
observed between the two subject groups. However, the median TI CD4+ T cell count/106 
epithelial cells was 2.4-fold lower in HIV+ subjects versus HNC (19,679 versus 47,504 
cells; p = 0.02). Similarly, median LC CD4+ T cell counts were reduced in HIV+ subjects 
(8,358 versus 18,577; p = 0.03) but were not reduced in RC. Importantly, we found no 
significant differences in Tfh or IgA+ B cell counts at either site between HIV+ subjects and 
HNC. Further analysis showed no difference in CD4+, Tfh, or IgA+ B cell counts between 
subjects who commenced ART in primary compared to chronic HIV-1 infection. Despite 
the decrease in total CD4 T cells, we could not identify a selective decrease of other 
key subsets of CD4+ T cells, including CCR5+ cells, CD127+ long-term memory cells, 
CD103+ tissue-resident cells, or CD161+ cells (surrogate marker for Th17), but there was 
a slight increase in the proportion of T regulatory cells.
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conclusion: While there were lower absolute CD4+ counts in the TI and LC in HIV+ 
subjects on ART, they were not associated with significantly reduced Tfh cell counts 
or IgA+ B cells, suggesting that this important vanguard of adaptive immune defense 
against luminal microbial products is normalized following ART.
Keywords: hiV, gut-associated lymphoid tissue, cD4+ T lymphocytes, T follicular helper cells, germinal centers, 
iga B cells
inTrODUcTiOn
Several studies have focused on the effect of primary HIV-1 
infection (PHI) on CD4+ T cells in gut-associated lymphoid tis-
sue (GALT) as a defining event in the pathogenesis of eventual 
chronic HIV-1 infection (CHI) [reviewed in Ref. (1, 2)]. GALT 
is widely believed to contain the majority of CD4+ T cells in 
the body, and PHI is believed to result in massive depletion of 
CD4+ T cells in the lamina propria (3–5), compared to the slower 
decline of CD4+ T cell counts in blood (6–8). In particular, the 
chronic T cell activation that is characteristic of untreated CHI 
may be due to damage to the epithelial barrier in GALT, leading 
to systemic translocation of microbial products into lymphoid 
tissues (2, 8–10), which in turn may lead to further systemic 
activation of CD4+ T cells and their continued depletion.
Potent antiretroviral therapy (ART), even when fully sup-
pressive for years, may not necessarily lead to full restoration 
of normal numbers of CD4+ T cells in GALT (11–13), and even 
commencing ART during PHI may not completely restore CD4+ 
T cells in GALT (11), unless subjects are treated during the very 
earliest stages of infection (14). This dysregulation of GALT may 
also lead to its role as a continuing reservoir for HIV-1 replica-
tion, despite ART (15, 16).
Most studies of CD4+ T cell depletion in GALT during HIV 
infection have particularly looked at a deficit in Th17 cells, since 
these are believed to contribute to epithelial cell barrier integrity 
(7, 10, 14, 17, 18). It has been reported that a large majority of 
CD4+ T lymphocytes in human GALT express CCR5 (19, 20) and 
that many of these cells are highly activated (21), making this sub-
population of CD4+ T cells highly susceptible to HIV-1 infection 
and depletion. Furthermore, it has been reported that T regula-
tory cells (Tregs) are significantly increased in tonsil tissue during 
HIV-1 infection (22) and also in GALT during untreated, but not 
treated, HIV-1 infection (23). Altogether, it is believed that normal 
CD4 T cell functions in GALT are significantly compromised in 
HIV-1 infection and may not be completely normalized by ART.
However, prior to reaching the epithelial cells, gut microbes 
must first penetrate the mucous layer in the lumen, and the 
front-line adaptive immune defense in this layer is IgA, produced 
locally and secreted into the lumen (24, 25). This IgA production 
in turn is largely dependent on CD4+ T cell help, mediated by 
T follicular helper (Tfh) cells in local germinal centers (GCs) (24).
Since large-scale depletion of CD4+ T cells has been reported 
in GALT, it is probable that Tfh are also depleted, and in fact, 
it has been reported that GCs in GALT have abnormally high 
levels of apoptosis during PHI (26) and GC may not normalize 
after ART (18). Furthermore, murine studies have suggested that 
gut Tfh develop from Th17 precursors (27), and Th17 cells are 
reportedly also lost very early in HIV-1 infection (7, 14, 18). We, 
and others, have recently found that Tfh cells in GCs, peripheral 
lymph nodes, and spleen are highly infected in both SIV and HIV 
infections (28–32). Taken together, we hypothesized that Tfh, 
along with other CD4+ T cell subsets in GALT, would be depleted 
early in HIV-1 infection and may not be fully reconstituted dur-
ing ART, which would in turn lead to a deficit of IgA+ B cells, 
further compromising the integrity of the epithelial barrier.
We aimed to identify and quantify the Tfh subset of CD4+ 
T cells, in gut biopsies from subjects on fully suppressive ART 
and also IgA+ B cells present in the same samples. At the same 
time, in comparison to the effect on Tfh, we also studied the effect 
of treated HIV-1 infection on other key subsets of CD4+ T cells, 
including CCR5+ memory CD4+ T cells, CD127+ long-term 
memory cells, CD103+ tissue-resident memory T (Trm) cells, 
CD161+ cells, which is a surrogate cell surface maker for Th17 
cells in human GALT (33), and CD25+CD127dim Tregs.
In addition to studying T lymphocyte subsets, we employed 
polychromatic flow cytometry to enumerate epithelial cells in 
the same single cell suspensions, using the cell surface marker 
EpCAM (CD326) (34). It has recently been suggested that pro-
liferation of gut epithelial cells is increased in CHI (35). In order 
to measure proliferating cells we measured Ki-67 expression in 
EpCAM+ cells by flow cytometry.
MaTerials anD MeThODs
subjects and Biopsy collection
Twenty-two HIV-uninfected healthy adult volunteers and 23 
HIV+ subjects on fully suppressive ART underwent colonoscopy 
to provide biopsy specimens, through the endoscopy unit at St 
Vincent’s Hospital, Sydney. The study protocols were approved 
by the Local Ethics Committee (references HREC 8/SVH/20 and 
HREC 11/SVH/193), and written informed consent was obtained 
from each participant. Subject demographics are shown in Table 
S1 in Supplementary Material.
Endoscopic biopsies from the left colon (LC), right colon 
(RC), and terminal ileum (TI) were obtained during colonos-
copy, with all biopsies taken from standardized sites, as previ-
ously described (36).
Biopsy Processing
Ten pinch biopsies taken from each site were placed in RPMI 
medium (Life Technologies) containing 10% fetal calf serum 
(FCS) (Bovogen, VIC, Australia), as well as 100 U of penicillin/
streptomycin (Life Technologies; R10/P/S) to minimize bacte-
rial contamination from the GALT samples (37). Biopsies were 
3Zaunders et al. Gut Tfh in HIV Infection
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 438
washed three times with HBSS (Life Technologies) containing 
1% PenStrep, 0.1M DTT (Life Technologies) (pH 8.0), and 0.15% 
EDTA (Sigma-Aldrich, MO, USA) (0.5M) (38) on a shaking 
incubator at 130 rpm at 37°C for 20 min. Supernatants collected 
after each wash step were retained for each site. Biopsies were 
then minced using sterile scissors and enzymatically digested 
with 200 U/ml collagenase type III (Sigma-Aldrich) (37–39) and 
200 mg/ml DNase (Sigma-Aldrich) in R10/P/S for 1 h at 37°C 
in a shaking incubator at 110 rpm. A single-cell suspension was 
prepared by pushing digested tissue through a 70-μm cell strainer 
for flow cytometry.
Monoclonal antibodies
Fluorochrome-conjugated monoclonal antibodies (mAbs) used in 
this study were CD45-PerCP and -Alexa Fluor 700, EpCam-FITC 
and -BV510, CD3-PerCP-Cy5.5, CD4-PE, -PE-Cy7, -BV786, and 
-AlexaFluor 700, CD8-APC-Cy7, CD45RA-BV605, HLA-DR-
FITC, and -APC-Cy7, CD38-APC and -PE-Cy7, CD25-APC 
and -BB515, CD127-PE-CF594, CD103-PE, CXCR5-Alexa Fluor 
647, CD16-BV421, and CD56-APC from BD Biosciences (San 
Jose, CA, USA); CD4+ 5RA-ECD (clone 2H4) from Beckman 
Coulter (Hialeah, FL, USA); CD127-eFluor450 and CD62L-
APC-eFluor780 from eBioscience (San Diego, CA, USA); PD-1 
(PE or APC, clone EH-12) and CD127-BV421 and -PE-Cy7 from 
BioLegend (San Diego, CA, USA); and IgA-PE and CD161-APC 
and -PE-Cy7 (Miltenyi Biotec, Germany). All antibodies were 
used according to the manufacturers’ directions.
For detection of surface markers, gut biopsy cells were stained 
with fluorochrome-conjugated antibodies for 15  min at room 
temperature, washed once with PBA [Dulbecco’s phosphate-
buffered saline (DPBS) containing 0.5% BSA and 0.1% sodium 
azide], and resuspended in 0.5% paraformaldehyde (Electron 
Microscopy Sciences, PA, USA) in DPBS (PFA) for fixation, 
as previously described for human immunophenotyping (40). 
Intracellular staining for Ki-67 was performed as previously 
described (40), and intracellular staining for Bcl-6 was performed 
as previously described (31).
ccr5 staining
An indirect immunofluorescence staining protocol (41) was 
optimized for detection of CCR5 (31, 42). Gut biopsy cells were 
stained with 10 μg/ml purified mAb against CCR5 (clone 2D7; 
BD Biosciences) for 15 min at RT, washed once with PBA, and 
incubated for 15 min at RT with a 1:50 dilution of PE-conjugated 
F(ab′)2 fragment goat anti-mouse IgG (H +  L chain-specific) 
PE (human, bovine, rabbit, swine serum protein absorbed) 
secondary antibody (Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA). Cells were then washed twice with PBA, 
blocked with 10% mouse serum for 10 min at room temperature, 
and stained with monoclonal antibodies to other surface proteins 
as described above. A negative control was performed in parallel, 
in which the primary anti-CCR5 mAb was not added.
Flow cytometry
Stained gut biopsy cells were analyzed on a four-laser BD LSR 
II with FACSDiva 6.0 software (BD Biosciences) as previously 
described (40, 43). Cells were gated first on a broad forward versus 
side scatter gate, then on a CD45 versus EpCAM plot to remove 
debris and epithelial cells, and define CD45+EpCAM− hemat-
opoietic cells (Figure 1A). CD3 was used to define T lymphocytes 
in the CD45+ gate, which were then gated on CD4+ and CD8 
and subsequently on various subsets as shown. CD19 was used to 
define B lymphocytes in the CD45+ gate, which were then gated 
on various subsets as indicated.
Cell counts, including CD4+ lymphocytes, in the single cell 
suspensions were determined by adding 100 μl of the single cell 
suspension preparation sample to mAbs in a TruCount tube (BD 
Biosciences), incubating for 15 min at RT, and fixing with 0.5-ml 
PFA, before analyzing by flow cytometry, as above. The number 
of cells in the 100-μl sample was calculated according to the 
manufacturer’s directions, and the total number of CD4+ T cells 
recovered was then determined.
statistical analysis
Data are shown as medians and interquartile ranges. Statistical sig-
nificance between subject groups was analyzed by Mann–Whitney 
test, with p < 0.05 considered statistically significant (PRISM 6, 
GraphPad Software, CA, USA). The correlation between Tfh cell 
numbers and IgA+ was analyzed by  non-parametric Spearman 
correlation (PRISM 6). Results for four patients who commenced 
therapy during PHI (36) were compared to all other HIV+ sub-
jects on ART by Mann–Whitney test.
resUlTs
epithelial cell counting in gut Biopsies
We used a polychromatic flow cytometry strategy of initial gating 
based on EpCAM staining of epithelial cells versus CD45 staining 
of lymphocytes, to accurately count both CD45+ lymphocytes 
and EpCAM+ epithelial cells in the single cell suspensions, using 
counting beads (Figure 1A).
The results show that the number of epithelial cells counted 
in biopsies was consistent between subject groups (Figure 1B). 
Minor variations in epithelial cell counts are in line with slight 
effects of variability in the amount of tissue obtained between 
specimens or in the efficiency of digestion between samples. 
The number of epithelial cells in each cell suspension was then 
used to normalize comparisons of lymphocyte counts between 
specimens (see below).
Since it has recently been suggested that proliferation of gut 
epithelial cells is increased in CHI (35), we measured Ki-67 
expression in EpCAM+ cells by flow cytometry. We found 
relatively low levels, with medians of 1.5–2.5% of epithelial cells 
that were Ki-67+, but no significant differences between subject 
groups (Figure 1C).
assessing cD4+ and cD8+ T cell numbers
Virtually, all CD45+ cells were CD3+ T lymphocytes and CD19+ 
B lymphocytes (Figure  1A, see lower middle flow plot), with 
very few cells identified as neutrophils (CD16+, side scatter high, 
CD45dim) or NK cells (CD56+CD45high) (data not shown). From 
these CD45+ lymphocyte populations, CD4+ T cell, CD8+ T cells, 
and B cell counts, respectively, were obtained from the TruCount 
FigUre 1 | (a) Sequential gating strategy to count lymphocytes and epithelial cells in gut biopsy specimens is shown in representative flow plots for an HIV-negative 
control adult terminal ileum biopsy. (B) Epithelial cell counts from HIV-negative controls (HNC) and HIV+ subjects on ART, respectively, for left colon (LC), right colon 
(RC), and terminal ileum (TI). (c) Proliferation rates of epithelial cells, measured as Ki-67+ % of EpCAM+ epithelial cells, in HIV-negative controls (HNC) compared with 
HIV+ subjects on ART.
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FigUre 2 | (a) CD4+ cell counts from gut biopsy single-cell suspensions 
from HIV-negative controls (HNC) compared with HIV+ subjects on ART, 
respectively, for left colon (LC), right colon (RC), and terminal ileum (TI). Open 
square symbols indicate HIV+ subjects who commenced ART during primary 
HIV-1 infection. (B) CD8+ cell counts from gut biopsy single cell suspensions 
from HIV-negative controls (HNC) compared with HIV+ subjects on ART, 
respectively, for left colon (LC), right colon (RC), and terminal ileum (TI). (c) 
CD4:CD8 ratios HIV-negative controls (HNC) compared with HIV+ subjects on 
ART, respectively, for left colon (LC), right colon (RC), and terminal ileum (TI).
5
Zaunders et al. Gut Tfh in HIV Infection
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 438
bead counts (Figure 1A), and calculated as the number of each 
subset per 106 epithelial cells.
The results show that there were just over twofold reductions 
in the CD4+ T cell counts from LC and TI biopsies from HIV+ 
subjects on ART compared to HIV-negative controls (HNC), 
respectively (Figure 2A), but no significant difference was seen 
for RC biopsies. Included in the HIV+ group were five subjects 
who commenced ART during PHI, as part of the PINT trial (36, 
44), and their LC and TI biopsies CD4+ T cell counts did not differ 
significantly from the other HIV+ subjects (Figure 2A).
There were no significant differences in CD8 T cell count 
(Figure 2B), but there were significant decreases in the CD4:CD8 
ratios in biopsies from LC and TI from the HIV+ subjects, 
compared to healthy adult controls (Figure 2C). The CD4:CD8 
ratios in the biopsies from HIV+ subjects were lower than the 
corresponding median ratio of 0.94 in peripheral blood (Table S1 
in Supplementary Material).
T Follicular helper cD4+ T cells, germinal 
center B cells, and iga+ B cells  
in gut Biopsies
An important function of CD4+ T lymphocytes in GALT is to 
provide help to local B cells to switch to IgA antibody production, 
which is then secreted into the lumen. IgA and the mucous layer 
provide first-line protection against pathogenic microbes and are 
integral to gut microbiome homeostasis (24, 25). This CD4+ T cell 
help to B cells is provided by a specialized subset of Tfh cells, 
which we identified in the gut biopsies as CD45RAnegPD-1high 
CXCR5+ (31); these cells also expressed the Tfh-lineage-specific 
transcription factor Bcl-6 (Figure S1 in Supplementary Material). 
The results show that there were no significant differences in 
the proportion of CD4+ T cells in gut biopsies that were Tfh 
(Figure  3A) between HIV+ and HNC subjects. Furthermore, 
there were no significant differences in Tfh cell counts in gut 
biopsy samples from HIV+ subjects on ART compared to healthy 
adult controls (Figure 3B).
We could also identify GC B cells in the gut biopsy samples as 
CD19+CD20highCD38highKi-67+ cells (Figure S2 in Supplementary 
Material), which is consistent with the detection of Tfh cells in 
the same samples.
IgA+ B cells in the gut biopsy samples were identified as 
CD19+IgD−CD27+IgA+ lymphocytes (Figure  3C). The overall 
results show that there was no significant difference in the number 
of IgA+ B cells in gut biopsy samples from HIV+ subjects on ART 
compared to healthy adult controls (Figure  3D). Importantly, 
there was a highly significant correlation between the number of 
Tfh cells and the number of IgA+ B cells in TI biopsies (Figure 3E; 
Spearman’s rho = 0.89; p < 0.001).
ccr5+cD4+ T cells
We also studied other important subsets of CD4+ T cells in the 
gut biopsies that may have been selectively depleted. We have 
recently optimized staining for CCR5 on CD4+ T lymphocytes 
in non-human primate lymphoid tissue (31) and human blood 
(42). Therefore, we re-evaluated CCR5 expression using the 
FigUre 3 | (a) PD-1highCXCR5+ Tfh cells % of CD4+ in gut biopsies from HIV-negative controls (HNC) compared with HIV+ subjects on ART, respectively, for left 
colon (LC), right colon (RC), and terminal ileum (TI). (B) Tfh cell counts in gut biopsies from HIV-negative controls (HNC) compared with HIV+ subjects on ART, 
respectively, for left colon (LC), right colon (RC), and terminal ileum (TI). Open square symbols indicate HIV+ subjects who commenced ART during primary HIV-1 
infection. (c) Representative flow plots showing gating for IgA+CD27+ B cells in gut biopsies. (D) IgA+CD27+ B cell counts in gut biopsies from HIV-negative controls 
(HNC) compared with HIV+ subjects on ART, respectively, for left colon (LC), right colon (RC), and terminal ileum (TI). Open square symbols indicate HIV+ subjects 
who commenced ART during primary HIV-1 infection. (e) Correlation between IgA+ B cell counts in terminal ileum (TI) and Tfh cell counts in terminal ileum (TI), for 
each individual subject. Open square symbols indicate HIV+ subjects who commenced ART during primary HIV-1 infection.
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FigUre 4 | (a) Indirect immunofluorescence to measure CCR5+CD4+ T cells. Representative flow plot on left shows negative control where anti-CCR5 primary 
monoclonal antibody was omitted. Flow plot on right shows CCR5 expression on memory (CD45RA−) CD4+ T cells from a TI biopsy from a healthy control (HNC). 
(B) CCR5+ % of memory CD4+ and CCR5+ % of memory CD45RO+CD8+ T cells in gut biopsies from HIV-negative controls (HNC) compared with HIV+ subjects on 
ART, respectively, for left colon (LC) and terminal ileum (TI). (c) Representative flow plot on right shows co-expression of CD38 and HLA-DR on CCR5+ memory 
CD4+ T cells (gated on left, from (a), above) from a TI biopsy from a healthy control (HNC). (D) Co-expression of CD38 and HLA-DR on CCR5+ memory CD4+ and 
CCR5+ memory CD8+ T cells, in gut biopsies from HIV-negative controls (HNC) compared with HIV+ subjects on ART, respectively, for left colon (LC) and terminal 
ileum (TI).
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optimized staining protocol (representative flow plots are shown 
in Figure 4A). Overall, approximately half of CD4+ T cells in the 
gut biopsies were CCR5+ (Figure 4B). We found no significant 
difference in the proportion of CD4+ T cells that were CCR5+ 
between HIV+ subjects and HNC (Figure  4B), suggesting that 
there was no selective depletion of the CCR5+ subset, and this did 
not account for the difference in CD4+ T cell counts.
In contrast to the CD4+ T cells, a much higher proportion of 
CD8+ T cells were also CCR5+, around 90%, from both subject 
groups (Figure 4B).
Also, we gated on the CCR5+CD4+ T cells in gut biopsies from 
healthy adult controls and studied co-expression of the activation 
markers CD38 and HLA-DR (representative flow data is shown 
in Figure 4C). Overall, we found that in HNC, <10% of either 
CCR5+CD4+ or CCR5+CD8+ T cells exhibited co-expression of 
CD38 and HLA-DR (Figure 4D), and there were no significant 
differences compared to HIV+ subjects.
Other Subsets of Memory CD4+ T Lymphocytes
We and others have found that the largest proportional decline in 
CD4+ T cells in blood during early HIV-1 infection is associated 
with loss of memory CD4+ T cells that express the alpha chain of 
the IL-7 receptor, CD127 (43, 45, 46), with eventual loss of IL-7 
homeostasis in late-stage disease (47). Therefore, we analyzed 
the CD127+ subset as a percentage of memory CD4+ T cells in 
gut biopsy samples, but found no significant differences between 
HIV+ subjects and HNC (Figure 5A).
Second, we differentiated between CD103+ intraepithelial, 
tissue-resident CD4+ T cells (48) versus transient CD103−CD4+ 
T cells. Here, we found that only a very small minority of CD4+ 
FigUre 5 | (a) CD127high % of memory CD45RO+CD4+ T cells in gut biopsies from HIV-negative controls (HNC) compared with HIV+ subjects on ART, respectively, 
for left colon (LC) and terminal ileum (TI). (B) CD103+ % of memory CD45RO+CD4+ and CD103+ % of memory CD45RO+CD8+ T cells in gut biopsies from 
HIV-negative controls (HNC) compared with HIV+ subjects on ART, respectively, for left colon (LC) and terminal ileum (TI). (c) CD161+ % of CD4+ T cells in gut 
biopsies from HIV-negative controls (HNC) compared with HIV+ subjects on ART, respectively, for left colon (LC) and terminal ileum (TI).  
(D) CD25highCD127dimCD45RO+ Tregs % of CD4+ T cells in gut biopsies from HIV-negative controls (HNC) compared with HIV+ subjects on ART, respectively, for left 
colon (LC) and terminal ileum (TI).
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T cells in LC biopsies were CD103+, but a larger proportion, 
around 20% of CD4+ T cells, were CD103+ in TI biopsies 
(Figure 5B). However, again, we found no significant differences 
in CD103+CD4+ T cells between biopsies from HIV+ subjects 
and HNC (Figure  5B). The proportion of CD8+ T cells that 
were CD103+ was much higher than for CD4+ T cells, with 50% 
or more of CD8+ T cells expressing CD103 in both LC and TI 
biopsies (Figure 5B).
It has been reported that Th17 CD4+ T cells are selectively 
reduced in GALT during HIV infection (14, 17, 18) and that this 
depletion may not be reversed by ART (7, 14, 18). Therefore, we 
studied the relative proportions of CD4+ T cells that expressed 
CD161, which includes Th17 cells in human GALT (33). 
However, the results show that there was no significant selective 
depletion of CD161+CD4+ T cells in gut biopsy samples from 
HIV+ subjects, with similar percentages compared to HNC 
(Figure 5C).
Finally, we also used the CD25+CD127dim phenotype to 
identify Tregs (49), although CD25 expression was not always as 
distinct in the gut biopsy preparations compared to that typically 
found on Tregs in peripheral blood (Figure S3 in Supplementary 
Material). Overall, we found a slight increase in the proportion 
of Tregs in CD4+ T cells in both LC and TI biopsies from HIV+ 
subjects, compared to HNC (Figure 5D). Interestingly, the pro-
portion of memory CD4+ T cells that were Tregs in TI biopsies 
from HNC was quite low compared to blood (43, 49), but even 
with the elevation seen in HIV+ subjects, Tregs remained quite a 
minor subset of CD4+ T cells in TI biopsies.
9Zaunders et al. Gut Tfh in HIV Infection
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DiscUssiOn
In this study, we aimed to quantify the level of depletion of impor-
tant subsets of CD4+ T cells in GALT biopsies from ART-treated 
HIV-1-infected subjects, compared to HNC, by accurate counting 
of single cell suspensions using polychromatic flow cytometry.
We used a novel approach of EpCAM staining of epithelial 
cells versus CD45+ staining of lymphocytes, to optimize detection 
of CD4+ T cells and minimize cell loss during processing. The 
total numbers of CD4+ T cells present in the gut biopsies from the 
HIV+ subjects on ART were at about half the normal level in TI 
and LC but with no significant difference in RC. There have been 
differing reports on whether CD4+ T lymphocytes are fully recon-
stituted in GALT following ART (50). Our results suggest that 
this may depend on which site has been studied, consistent with 
a recent report comparing different sites of GALT biopsies (51). 
In a limited number of subjects who commenced ART during 
PHI, there was no clear difference in CD4 T cell counts compared 
to the remainder of the cohort studied, who commenced ART 
during CHI.
Previous studies have mainly used histological enumeration 
of CD4+ and CD8+ T cells in the context of HIV infection, and 
most previous studies have reported depletion of CD4+ T cells 
as a percentage of CD3+ lymphocytes (5, 17). We measured the 
absolute numbers of cells and found a decrease in the CD4:CD8 
ratio, consistent with previous results (51).
One of the main aims of this study was to assess eventual 
changes in the number of Tfh cells in GALT in patients with HIV 
infection on ART. This is the first study to comprehensively study 
the Tfh subset of CD4+ T cells and the IgA+ B cell subset in human 
gut biopsies during HIV-1 infection. We and others have recently 
shown dysregulation of Tfh numbers in peripheral lymph nodes 
and spleen, during either SIV or HIV infections (28–32), includ-
ing evidence of infection of Tfh (30–32, 52). In all these reports, 
the proportion of Tfh increased, rather than decreased, compared 
to other memory CD4+ T cells in lymphoid tissue. Nevertheless, 
based on the descriptions of very extensive CD4+ T cell depletion 
in GALT during primary infection, and also dysfunction of GCs 
(26), we hypothesized that Tfh were irreversibly lost. However, 
in treated HIV+ subjects, the numbers of Tfh cells in gut biopsies 
were within the observed normal range.
Consistent with this normal number of Tfh cells, we also found 
that the number of IgA+ B cells was within the normal range in 
HIV+ subjects on ART. The local production of IgA is believed 
to be one of the main defense mechanisms within the GI tract, 
yet there have been few studies of the effect of HIV-1 infection 
on IgA+ B cells in GALT. In the study that suggested that GC 
formation was dramatically affected by PHI (26), longitudinal 
studies following ART were not performed. One other study also 
reported a finding of hyperactivity of B cells in GALT during late 
stage infection, using immunohistochemistry (53), similar to 
that which has been found in peripheral lymph nodes, and that 
the hyperactivity was rectified by ART. This normalization even 
when therapy is commenced in late-stage disease is consistent 
with our current findings on numbers of IgA+ B cells by flow 
cytometry. Furthermore, the close correlation between Tfh cell 
counts and IgA+ B cell counts is consistent with a very close 
functional relationship, normalized in HIV+ subjects on ART. 
Further studies should confirm whether luminal concentrations 
of IgA are also within the normal range.
One limitation of the current study is that we do not have 
Tfh or IgA+ B cell counts during PHI, prior to commencing 
therapy, and therefore, we cannot determine whether these 
cells were preserved or restored. Nevertheless, the observed 
numbers of Tfh cells and the IgA+ B cells in GALT after ART 
suggest that irreversible disruption of the homeostasis of the 
microbiome and subsequent microbial translocation after ART 
may not be as severe as currently believed. Previous results, 
based on immunohistochemistry of biopsies, had suggested 
disruptions to the epithelial barrier [reviewed in Ref. (10)], 
with a recent report of excessive proliferation and apoptosis 
of epithelial cells in CHI (35). We found no difference in the 
number of epithelial cells between controls and HIV+ subjects, 
and we have been unable to find significant disruption of 
the epithelial barrier using the technique of in  vivo confocal 
endomicroscopy (54).
The main cause of the massive depletion of CD4+ T cells 
from GALT during primary HIV or SIV infection is believed to 
be high expression of CCR5 on CD4+ T cells, as well as activa-
tion due to the presence of microbial products (6). However, 
using an optimized method for staining for CCR5, we found 
that typically less than half of CD4+ T cells in the gut biopsy 
samples were CCR5+ in healthy adult controls, and only a few 
of these cells expressed markers of activation. We can exclude 
an effect of enzymatic digestion during the single cell prepara-
tion on the detection of either CCR5 or activation markers, 
since nearly all CD8+ T cells were positive for CCR5 in the 
same preparations, and CD38 and HLA-DR were both present 
on B cells as expected (data not shown). One previous study 
showing high levels of CCR5 expression was based on CD45+ 
mononuclear cells and did not distinguish between CD4+ and 
CD8+ T cells (20). In that study, a high proportion of CCR5+ 
CD8+ T cells may therefore have masked a lower proportion 
on CD4+ T cells.
Also, we know from studies of circulating CD4+ T cells that 
there is an elevation of CCR5+ activated CD4+ T cells during 
PHI (55, 56), as well as following vaccinia inoculation (40), and 
this is consistent with elevated expression of CCR5 on CD4+ 
T cells in GALT once PHI is established (21). Nevertheless, it 
is believed that under usual steady-state conditions, GALT is 
normally more anti-inflammatory than proinflammatory (57, 
58). Furthermore, it is probable that the majority of CD4+ T cells 
in GALT recirculate, based on their low level of expression of 
CD103 reported in this study, and on mathematical modeling of 
CD4+ perturbations after large-scale apheresis (59). Conversely, 
parabiosis experiments in mice demonstrate a slow and incom-
plete equilibration of CD8+ T  cells between blood and GALT 
(60), consistent with our finding of higher expression of CD103 
on CD8+ T cells. Therefore, taken altogether, it seems unlikely 
that healthy adults have a preponderance of pre-existing, acti-
vated, and resident CCR5+CD4+ T cells in the GALT, prior to 
HIV-1 infection.
In our assessments of subsets of CD4+ T cells, we found no 
proportional differences in CD103+CD4+ T cells, believed to 
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represent intraepithelial/tissue-resident cells (48). Although 
it has been suggested that preparations of cell suspensions for 
flow cytometry give a different result for tissue-resident T cells 
compared to histology (61), this was described in lung tissue 
and was mainly due to circulating cells within microvascu-
lature in the lung tissue. Our gut biopsy samples were neither 
significantly contaminated with blood, as indicated by lack of 
neutrophils and NK cells, nor did they contain visible red cells 
(data not shown). We rigorously and accurately defined CD4+  
T cells using polychromatic flow cytometric techniques, exclud-
ing possible non-specific staining due to non-lymphoid cells, B 
cells, or myeloid cells.
Finally, previous studies of subsets of CD4+ T cells in gut 
biopsies during HIV infection have concentrated on the Th17 
subset of CD4+ T cells, since it is believed they are essential 
to maintenance of the epithelial cell barrier (10), but we did 
not find any significant selective effect on CD161+CD4+ T cells, 
which are known to include Th17 cells in gut (33). Also, we 
found only a slight increase in the proportion of Treg cells, 
which is consistent with our previous results that the majority 
of Tregs in blood do not express the gut-homing integrins α4 
and β7 (62).
In conclusion, the results of this study suggest that, consist-
ent with previous reports (50), ART-treated HIV+ subjects may 
not completely normalize their total CD4+ T cell populations 
in GALT, but their important Tfh/GC/IgA axis of immunity is 
relatively normal.
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FigUre s1 | Tfh cells in gut biopsies were identified as cD45ra−PD-
1highcXcr5+cD4+ T cells (representative flow plot on left) with 
confirmation of expression of the lineage-specific transcription factor 
Bcl-6 (right), in Ti biopsy from an hiV-negative control.
FigUre s2 | germinal centre B cells in gut biopsies were identified as 
cD19+cD38high (representative flow plot on left) and cD20highBcl-6+ (right), 
in Ti biopsy from an hiV-negative control.
FigUre s3 | sequential gating strategy to identify T regulatory cells 
(Tregs) in gut biopsies as cD4+cD45ra−cD127dimcD25high. Representative 
flow plots are shown for an LC biopsy from an HIV-negative control.
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